Modulation of aberrant NF1 pre-mRNA splicing by kinetin treatment

European Journal of Human Genetics

Volumn 18, Issue 5, 2010, Pages 614-617

  Pros, Eva ^a   Fernández Rodríguez, Juana ^a   Benito, Llcia ^b   Ravella, Anna ^c   Capellá, Gabriel ^a   Blanco, Ignacio ^b   Serra, Eduard ^d   Lázaro, Conxi ^a  

^a HOSPITAL DURAN I REYNALS   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c Hospital Cruz Roja   (Spain)

^d Institut de Medicina Predictiva i Personalitzada del Cancer IMPPC   (Spain)

Author keywords

Aberrant splicing; Drug treatment; Kinetin; Neurofibromatosis type 1; Normal splicing restoration; Splicing mutations

Indexed keywords

ACLARUBICIN; BUTYRIC ACID; EPIGALLOCATECHIN GALLATE; KINETIN; MESSENGER RNA; NEUROFIBROMIN; VALPROIC ACID;

ARTICLE; CELL CULTURE; CELL LINE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; EXON SKIPPING; GENE MUTATION; HETEROZYGOSITY; HUMAN; HUMAN CELL; LYMPHOCYTE CULTURE; NEUROFIBROMATOSIS; PRIORITY JOURNAL; RNA SPLICING;

EID: 77951623402     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2009.212     Document Type: Article

References (14)

1. Messiaen L, Wimmer K: NF1 mutational spectrum; in: Kaufmann D (ed): Neurofi-bromatoses. Karger: Basel. Monogr Hum Genet 2008; 16: 63-77.
2. Pros E, Gomez C, Martin T, Fabregas P, Serra E, Lazaro C: Nature and mRNA effect of 282 different NF1 point mutations: focus on splicing alterations. Hum Mutat 2008; 29: E173-E193.
3. Chang JG, Hsieh-Li HM, Jong YJ, Wang NM, Tsai CH, Li H: Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci USA 2001; 98: 9808-9813.
4. Andreassi C, Jarecki J, Zhou J et al: Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum Mol Genet 2001; 10: 2841-2849.
5. Brichta L, Hofmann Y, Hahnen E et al: Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 2003; 12: 2481-2489.
6. Nissim-Rafinia M, Aviram M, Randell SH et al: Restoration of the cystic fibrosis transmembrane conductance regulator function by splicing modulation. EMBO Rep 2004; 5: 1071-1077.
7. Slaugenhaupt SA, Mull J, Leyne M et al: Rescue of a human mRNA splicing defect by the plant cytokinin kinetin. Hum Mol Genet 2004; 13: 429-436.
8. Anderson SL, Qiu J, Rubin BY: EGCG corrects aberrant splicing of IKAP mRNA in cells from patients with familial dysautonomia. Biochem Biophys Res Commun 2003; 310: 627-633.
9. Hims MM, Ibrahim EC, Leyne M et al: Therapeutic potential and mechanism of kinetin as a treatment for the human splicing disease familial dysautonomia. J Mol Med 2007; 85: 149-161.
10. Buratti E, Baralle M, Baralle FE: Defective splicing, disease and therapy: searching for master checkpoints in exon definition. Nucleic Acids Res 2006; 34: 3494-3510.
11. Baralle M, Skoko N, Knezevich A et al: NF1 mRNA biogenesis: effect of the genomic milieu in splicing regulation of the NF1 exon 37 region. FEBS Lett 2006; 580: 4449-4456.
12. Pros E, Larriba S, Lopez E et al: NF1 mutation rather than individual genetic variability is the main determinant of the NF1-transcriptional profile of mutations affecting splicing. Hum Mutat 2006; 27: 1104-1114.
13. Pros E, Fernandez-Rodriguez J, Canet B et al: Antisense therapeutics for neurofibro-matosis type 1 caused by deep intronic mutations. Hum Mutat 2009; 30: 454-462.
14. Gold-von Simson G, Goldberg JD, Rolnitzky LM et al: Kinetin in familial dysautonomia carriers: implications for a new therapeutic strategy targeting mRNA splicing. Pediatr Res 2009; 65: 341-346.